Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

502 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Literature review of visual representation of the results of benefit-risk assessments of medicinal products.
Hallgreen CE, Mt-Isa S, Lieftucht A, Phillips LD, Hughes D, Talbot S, Asiimwe A, Downey G, Genov G, Hermann R, Noel R, Peters R, Micaleff A, Tzoulaki I, Ashby D; PROTECT Benefit-Risk group. Hallgreen CE, et al. Among authors: downey g. Pharmacoepidemiol Drug Saf. 2016 Mar;25(3):238-50. doi: 10.1002/pds.3880. Epub 2015 Nov 2. Pharmacoepidemiol Drug Saf. 2016. PMID: 26521865 Free article. Review.
Recommendations for benefit-risk assessment methodologies and visual representations.
Hughes D, Waddingham E, Mt-Isa S, Goginsky A, Chan E, Downey GF, Hallgreen CE, Hockley KS, Juhaeri J, Lieftucht A, Metcalf MA, Noel RA, Phillips LD, Ashby D, Micaleff A; PROTECT Benefit-Risk Group. Hughes D, et al. Pharmacoepidemiol Drug Saf. 2016 Mar;25(3):251-62. doi: 10.1002/pds.3958. Epub 2016 Jan 22. Pharmacoepidemiol Drug Saf. 2016. PMID: 26800458 Free article.
Balancing benefit and risk of medicines: a systematic review and classification of available methodologies.
Mt-Isa S, Hallgreen CE, Wang N, Callréus T, Genov G, Hirsch I, Hobbiger SF, Hockley KS, Luciani D, Phillips LD, Quartey G, Sarac SB, Stoeckert I, Tzoulaki I, Micaleff A, Ashby D; IMI-PROTECT benefit-risk participants. Mt-Isa S, et al. Pharmacoepidemiol Drug Saf. 2014 Jul;23(7):667-78. doi: 10.1002/pds.3636. Epub 2014 May 13. Pharmacoepidemiol Drug Saf. 2014. PMID: 24821575 Review.
Benefit-risk assessment in a post-market setting: a case study integrating real-life experience into benefit-risk methodology.
Hallgreen CE, van den Ham HA, Mt-Isa S, Ashworth S, Hermann R, Hobbiger S, Luciani D, Micaleff A, Thomson A, Wang N, van Staa TP, Downey G, Hirsch I, Hockley K, Juhaeri J, Metcalf M, Mwangi J, Nixon R, Peters R, Stoeckert I, Waddingham E, Tzoulaki I, Ashby D, Wise L. Hallgreen CE, et al. Among authors: downey g. Pharmacoepidemiol Drug Saf. 2014 Sep;23(9):974-83. doi: 10.1002/pds.3676. Epub 2014 Jul 5. Pharmacoepidemiol Drug Saf. 2014. PMID: 25043919 Free article.
Risk of acute liver injury associated with use of antibiotics. Comparative cohort and nested case-control studies using two primary care databases in Europe.
Brauer R, Douglas I, Garcia Rodriguez LA, Downey G, Huerta C, de Abajo F, Bate A, Feudjo Tepie M, de Groot MC, Schlienger R, Reynolds R, Smeeth L, Klungel O, Ruigómez A. Brauer R, et al. Among authors: downey g. Pharmacoepidemiol Drug Saf. 2016 Mar;25 Suppl 1:29-38. doi: 10.1002/pds.3861. Pharmacoepidemiol Drug Saf. 2016. PMID: 27038354
Prevalence of antibiotic use: a comparison across various European health care data sources.
Brauer R, Ruigómez A, Downey G, Bate A, Garcia Rodriguez LA, Huerta C, Gil M, de Abajo F, Requena G, Alvarez Y, Slattery J, de Groot M, Souverein P, Hesse U, Rottenkolber M, Schmiedl S, de Vries F, Tepie MF, Schlienger R, Smeeth L, Douglas I, Reynolds R, Klungel O. Brauer R, et al. Among authors: downey g. Pharmacoepidemiol Drug Saf. 2016 Mar;25 Suppl 1(Suppl Suppl 1):11-20. doi: 10.1002/pds.3831. Epub 2015 Jul 7. Pharmacoepidemiol Drug Saf. 2016. PMID: 26152658 Free PMC article.
Ascertainment of acute liver injury in two European primary care databases.
Ruigómez A, Brauer R, Rodríguez LA, Huerta C, Requena G, Gil M, de Abajo F, Downey G, Bate A, Tepie MF, de Groot M, Schlienger R, Reynolds R, Klungel O. Ruigómez A, et al. Among authors: downey g. Eur J Clin Pharmacol. 2014 Oct;70(10):1227-35. doi: 10.1007/s00228-014-1721-y. Epub 2014 Jul 29. Eur J Clin Pharmacol. 2014. PMID: 25066450
Inpatient drug utilization in Europe: nationwide data sources and a review of publications on a selected group of medicines (PROTECT project).
Sabaté M, Ferrer P, Ballarín E, Rottenkolber M, Amelio J, Schmiedl S, Reynolds R, Klungel O, Ibáñez L; PROTECT Work Package 2. Sabaté M, et al. Basic Clin Pharmacol Toxicol. 2015 Mar;116(3):201-11. doi: 10.1111/bcpt.12358. Epub 2014 Dec 29. Basic Clin Pharmacol Toxicol. 2015. PMID: 25420967 Free article. Review.
A compilation of research working groups on drug utilisation across Europe.
Sabaté M, Pacheco JF, Ballarín E, Ferrer P, Petri H, Hasford J, Schoonen MW, Rottenkolber M, Fortuny J, Laporte JR, Ibáñez L; PROTECT Work Package 2. Sabaté M, et al. BMC Res Notes. 2014 Mar 13;7:143. doi: 10.1186/1756-0500-7-143. BMC Res Notes. 2014. PMID: 24625054 Free PMC article.
Adjustment for continuous confounders: an example of how to prevent residual confounding.
Groenwold RH, Klungel OH, Altman DG, van der Graaf Y, Hoes AW, Moons KG; PROTECT WP2 (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium, Work Programme 2 [Framework for pharmacoepidemiology studies]). Groenwold RH, et al. CMAJ. 2013 Mar 19;185(5):401-6. doi: 10.1503/cmaj.120592. Epub 2013 Feb 11. CMAJ. 2013. PMID: 23401401 Free PMC article. Review. No abstract available.
502 results